I. MODIFIED AGREEMENTS

Biotech Co.*
(Country;
Symbol)

Pharma Co. (Country)

Change from original agreement

Terms/Details (Date)


Cepheid Inc.
(CPHD)

Applera Corp.

They amended patent license agreement relating to real-time thermal cycler instruments

Cepheid's license now includes diagnosis and monitoring of HIV and hepatitis C infections; terms were not disclosed (6/29)

CuraGen
Corp.
(CRGN)

Bayer Pharmaceuticals Corp.

Bayer announced its intention to license BAY 76-7171 (formerly CT052), a diabetes drug candidate

CuraGen previously opted to receive a tiered royalty structure for the drug and no longer is contributing to development (7/19)

Gen-Probe
Inc.
(GPRO)

Bayer Healthcare LLC (Germany)

The companies agreed to end a series of disputes involving patent litigations and contract arbitrations

As part of the deal, Bayer will pay Gen- Probe certain lump sum royalties over 18 months; dispute areas included nucleic acid diagnostics and viral products (6/22)

SkyePharma
plc
(UK; SKYE)

Mundipharma International Holdings Ltd. (UK)

SkyePharma reacquired rights to DepoBupivacaine in Europe and other markets excluding the U.S., Canada and Japan

SkyePharma is paying $5M for the rights; it intends to divest its injectables unit, of which the product is a part (6/30)

I. TERMINATED AGREEMENTS

Antisoma plc
(UK; LSE:ASM)

F. Hoffmann- La Roche Ltd. (Switzerland)

Antisoma regained all rights to the investigational cancer drug AS1404 from Roche

Antisoma plans to move the agent into Phase III trials in lung cancer; Roche also declined to exercise its option on another compound, R1550 (now AS1402) (6/4)

EPIX
Pharmaceuticals
Inc.
(EPIX)

Schering AG (Germany)

Schering will not exercise its option for EPIX's fibrin-binding imaging agent EP-2104R

EPIX has full rights to the product and intends to find a new partner (7/13)

Neurocrine
Biosciences
Inc.
(NBIX)

Pfizer Inc.

They terminated December 2002 deal to develop and co-promote the insomnia drug candidate indiplon

The move followed word from the FDA that additional testing likely would be needed to gain approval; Neurocrine regained all rights, and intends to continue development (6/22)

NexMed Inc.
(NEXM)

Schering AG (Germany)

Schering terminated a deal from July 2004 that gave it rights to Alprox-TD outside the U.S. and east Asia

Alprox-TD is a topical treatment in development for erectile dysfunction; NexMed gets a $0.5M termination fee (6/26)

SuperGen
Inc.
(SUPG)

Wyeth

They terminated deal under which Wyeth distributed the hairy cell leukemia product Nipent

SuperGen paid Wyeth a $2.1M early termination fee, and has taken over distribution (6/6)


Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange.